Regenxbio Inc
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne ; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku ; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis ' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people.
Current Price
$5.72
-8.41%GoodMoat Value
$8.23
43.9% undervaluedRegenxbio Inc (RGNX) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Regenxbio Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $87.82M. Gross profit (TTM) is $59.89M. EBITDA is $-229.35M. Earnings per share (EPS) is $-3.76. The P/E ratio is -1.02. Market capitalization is $295.23M.
Free cash flow (FCF) is $-126.38M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Regenxbio Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
